This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Sheldon Rubenfeld, MD; Bernard M. Patten, MD; Peter O. Kohler, MD

Arch Intern Med. 1978;138(7):1106-1108.

Abstract
Eleven patients with Graves' disease were treated with guanadrel sulfate and observed for changes in neuromuscular and cardiovascular manifestations. No notable changes in pulse rate or muscle strength were detected in either these patients during a three-day pretreatment period or in five control patients with Graves' disease receiving placebo for six days. Thyroid hormone levels were not altered by seven days of guanadrel sulfate therapy (5 to 20 mg orally every six hours), and no adverse side effects were encountered. Mean supine resting pulse fell from 102 ± 6 (mean ± SEM) to 90 ± 3 beats per minute (P <.02). The patients' proximal and distal muscle strengths were initially decreased, when compared with healthy subjects, and improved substantially with guanadrel therapy. We conclude that guanadrel sulfate may be useful in the symptomatic management of patients with thyrotoxicosis.

(Arch Intern Med 138:1106-1108, 1978)

Author Affiliations
From the Division of Endocrinology and Metabolism, Departments of Medicine and Neurology, Baylor College of Medicine, Houston. Dr Kohler is an Investigator of the Howard Hughes Medical Institute.

Footnotes
Accepted for publication Aug 10, 1977.

Presented at the American Federation for Clinical Research, Southern Section, New Orleans, Jan 20, 1977.

Reprint requests to Department of Medicine, Baylor College of Medicine, 1200 Moursund Ave, Houston, TX 77030 (Dr Rubenfeld).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?